Current Research Studies

A PHASE II RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING EFFECT OF GLCNAC ON TEAR PRODUCTION IN INDIVIDUALS WITH NGLY1-CDDG

NGLY-1 Trial

Phase: II
Clinicaltrials.gov ID: NCT05402345

What is the goal of the study?

Patients with NGLY1-CDDG will be randomly assigned in a 1:1 ratio to receive either N-acetylglucosamine (GlcNAc) or placebo 3 times per day for 6 weeks. The primary efficacy endpoint is change in tear production between baseline and 6 weeks as measured by the Schirmer II test.

Who can participate in the study?

Please contact the study team listed below to learn more.

Study Team:

PI (Study Doctor): Christina Lam
Study Team Member: Seishu Horikoshi, [email protected]